Following the publication of a peer-reviewed paper in Frontiers in Immunology detailing results from the POLB 001 LPS challenge trial, we catch up with Poolbeg Pharma's CEO Jeremy Skillington and COO Liam Tremble. Liam explains why this publication is a key validation milestone for POLB 001 and how it supports continued clinical development, including the upcoming TOPICAL trial. Jeremy provides an update on trial preparations, outlines interest from potential partners, and addresses a recent option exercise announcement involving former employees. This timely discussion offers investors fresh insights into Poolbeg’s 2024 roadmap.